Please assess the completion status of the following clinical trial:

Trial Title: SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>18 years of age~* RA for \>=6 months~* Receiving outpatient treatment~* Ongoing treatment with methotrexate for \>=3 months, stable for \>=1 month~* Inadequate response or intolerance to etanercept, infliximab or adalimumab~Exclusion Criteria:~* Previous treatment with MabThera~* Concurrent treatment with any anti TNF-alfa therapy or biologic therapy~* Previous treatment with any investigational cell-depleting therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 1000 mg IV rituximab
- B (Type: EXPERIMENTAL): 2 x 1000 mg IV rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).